Source comparison
BPC-157 for Post Concussion Syndrome Research: Comparison
Mechanism GABA receptor modulation, dopamine synthesis stabilisation, angiogenesis via VEGF upregulation Phospholipid precursor supporting membrane repair Anti-inflammatory via prostaglandin inhibition BPC-157 addresses neurotransmitter dysfunction; citicoline
This comparison does not assign a generated winner or score.
- Mechanism
- GABA receptor modulation, dopamine synthesis stabilisation, angiogenesis via VEGF upregulation
- Phospholipid precursor supporting membrane repair
- Anti-inflammatory via prostaglandin inhibition
- BPC-157 addresses neurotransmitter dysfunction; citicoline targets structural repair; omega-3s reduce inflammation
- Preclinical Evidence
- 35–50% reduction in lesion volume, 40% improvement in memory tests (rodent TBI models)
- Modest improvements in attention and processing speed in human trials
- Mixed results; some trials show benefit, others no effect
- BPC-157 shows strongest mechanistic plausibility but lacks human trial data
- Typical Dosing (Extrapolated)
- 700–3,500 mcg daily (subcutaneous or intranasal)
- 1,000–2,000 mg daily (oral)
- 2–4 grams DHA/EPA daily (oral)
- BPC-157 requires injection or intranasal delivery; oral agents offer convenience
- Human Clinical Trials
- Zero completed trials as of 2026
- Multiple phase II/III trials; modest effect sizes
- Multiple trials; inconsistent results
- Citicoline has the strongest clinical validation for PCS; BPC-157 remains investigational
- Regulatory Status
- Research-grade peptide; not FDA-approved for any indication
- Available over-the-counter; FDA-approved in some countries
- Generally Recognised As Safe (GRAS)
- BPC-157 exists in a regulatory grey area; citicoline and omega-3s are accessible